Needham analyst Ami Fadia reiterated a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) on Tuesday, setting a price target of $55, which is approximately 31.93% above the present share price of $41.69.
Fadia expects Intra-Cellular Therapies to post earnings per share (EPS) of -$0.85 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Intra-Cellular Therapies, with an average price target of $51.8.
The analysts price targets range from a high of $70 to a low of $44.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $19.01 million and a net profit of -$69.14 million. The company's market cap is $3.39 billion.
According to TipRanks.com, Needham analyst Ami Fadia is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.8% and a 44.76% success rate.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.